临床T1-3N1M0期乳腺癌新辅助化疗及改良根治术后腋窝淋巴结病理阴性患者术后放疗的作用
回顾性分析185例临床T1-3N1M0期乳腺癌经新辅助化疗和改良根治术后达腋窝淋巴结病理阴性(ypN0)患者,89例接受术后放疗、96例未放疗。术后放疗组5年远处转移率低于未放疗组(5.1%对15.0%,P=0.023),5年无病生存率高于未放疗组(95.0%对79.0%,P=0.008)。Ⅲ期患者中放疗组5年局部区域复发率低于未放疗组(1.9%对14.4%,P=0.041)。
要点
- 全组5年局部区域复发率4.5%、远处转移率10.4%、无病生存率86.6%、总生存率97.1%。
- 术后放疗组较未放疗组5年远处转移率降低(5.1%对15.0%,P=0.023),无病生存率升高(95.0%对79.0%,P=0.008)。
- Ⅲ期患者术后放疗组较未放疗组5年局部区域复发率降低(1.9%对14.4%,P=0.041)。
核心结论
- 临床T1-3N1M0期乳腺癌新辅助化疗和改良根治术后达ypN0患者局部区域复发率较低,术后放疗能降低远处转移率并提高无病生存率,且可降低临床Ⅲ期患者的局部区域复发率。
- 作者认为Ⅲ期患者需要术后放疗,Ⅱ期患者的放疗价值需要进一步研究。
研究设计与样本
- 回顾性分析1999—2013年中国医学科学院肿瘤医院收治的185例临床T1-3N1M0期乳腺癌患者,所有患者均完成新辅助化疗和改良根治术并达ypN0。
- 89例行术后放疗,96例未行放疗;Ⅱ期患者101例,Ⅲ期患者84例。
主要发现
- 全组5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4.5%、10.4%、86.6%和97.1%。
- 放疗组与未放疗组5年局部区域复发率分别为1.1%和7.5%(P=0.071),5年远处转移率分别为5.1%和15.0%(P=0.023),5年无病生存率分别为95.0%和79.0%(P=0.008),5年总生存率分别为100.0%和94.5%(P=0.089)。
- Ⅲ期患者中放疗组与未放疗组5年局部区域复发率分别为1.9%和14.4%(P=0.041),5年无病生存率分别为91.9%和67.4%(P=0.022)。
- Ⅱ期患者中放疗组与未放疗组5年远处转移率分别为0和11.5%(P=0.044),5年无病生存率分别为100.0%和84.9%(P=0.023)。
关键数值与推荐
- 单因素分析显示,有无脉管瘤栓是影响5年局部区域复发率的主要因素(P=0.001)。
- 单因素分析显示,年龄和有无辅助放疗是影响5年远处转移率的主要因素(均P<0.05),有无放疗是影响5年无病生存率的主要因素(P=0.008)。
- 单因素分析显示,病理T分期、原发灶新辅助化疗病理反应是影响5年总生存率的主要因素(均P<0.05)。
临床怎么用
- 作者认为Ⅲ期患者需要术后放疗。
- 作者认为Ⅱ期患者的放疗价值需要进一步研究。
局限性
- 原文未报告局限性,但结论中提出Ⅱ期患者的放疗价值需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the outcomes of clinical T1-3N1M0 breast cancer patients with pathological negative axillary lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) and mastectomy, and investigate the role of postmastectomy radiotherapy (PMRT). Methods: A total of 185 patients with clinical T1-3N1M0 breast cancer treated between 1999 and 2013 were retrospectively reviewed. All patients were treated with NAC and mastectomy, and achieved ypN0. Of them, 89 patients received additional PMRT and 96 patients did not. 101 patients had clinical stage Ⅱ disease. 84 patients had clinical stage Ⅲ disease. The rates of locoregional recurrence (LRR), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS) were calculated using the Kaplan-Meier method, and differences were compared using the log-rank test. Univariate analysis was used to interpret the impact of clinical features and treatment on patients' outcome. Results: The 5-year rates of LRR, DM, DFS, and OS for all patients were 4.5%, 10.4%, 86.6%, and 97.1%, respectively. For patients with and without PMRT, the 5-year LRR rates were 1.1% and 7.5% (P=0.071), the 5-year DM rates were 5.1% and 15.0% (P=0.023), the 5-year DFS rates were 95.0% and 79.0% (P=0.008), and the 5-year OS rates were 100.0% and 94.5% (P=0.089) respectively. In univariate analysis, lymph-vascular space invasion (LVSI) was poor prognostic factor of LRR (P=0.001), < 40 years old and lack of PMRT was a poor prognostic factor for DM (P<0.05), lack of PMRT was a poor prognostic factor for DFS (P=0.008), primary lesion residual and mild-moderate pathological response to NAC were poor prognostic factors for OS (P<0.05). In the subgroup of Stage Ⅲ disease, for patients with and without PMRT, the 5-year LRR rates were 1.9% and 14.4% (P=0.041), the 5-year DFS rates were 91.9% and 67.4% (P=0.022), respectively. In the subgroup of Stage Ⅱ disease, for patients with and without PMRT, the 5-year DM rates were 0 and 11.5% (P=0.044), the 5-year DFS rates were 100.0% and 84.9% (P=0.023), respectively. Conclusions: The LRR rate of clinical T1-3N1M0 breast cancer patients who achieved ypN0 after NAC and mastectomy was low. PMRT decreased the DM rate and increased DFS rate in all patients, and significantly decreased the LRR rate in Stage Ⅲ disease. PMRT should be considered for patients with Stage Ⅲ disease, and further research is warranted to investigate the benefit of PMRT for Stage Ⅱ disease. 目的: 分析临床T1~3N1M0期乳腺癌患者经新辅助化疗(NAC)和改良根治术后达到腋窝淋巴结病理阴性(ypN0)患者术后放疗的价值和预后。 方法: 回顾性分析1999—2013年中国医学科学院肿瘤医院收治的185例临床诊断为T1~3N1M0期乳腺癌患者的临床资料,所有患者均完成NAC和改良根治术,术后达ypN0。89例行术后放疗,96例未行放疗。Ⅱ期患者101例,Ⅲ期患者84例。采用Kaplan-Meier法计算局部区域复发率、远处转移率、无病生存率和总生存率,并行Log rank检验,单因素分析临床特征和治疗对患者预后的影响。 结果: 全组患者的5年局部区域复发率、远处转移率、无病生存率和总生存率分别为4.5%、10.4%、86.6%和97.1%。放疗组和未放疗组患者的5年局部区域复发率分别为1.1%和7.5%,差异无统计学意义(P=0.071);5年远处转移率分别为5.1%和15.0%,差异有统计学意义(P=0.023);5年无病生存率分别为95.0%和79.0%,差异有统计学意义(P=0.008);5年总生存率分别为100.0%和94.5%,差异无统计学意义(P=0.089)。单因素分析结果显示,有无脉管瘤栓是影响患者5年局部区域复发率的主要因素(P=0.001),年龄和有无辅助放疗是影响患者5年远处转移率的主要因素(均P<0.05),有无放疗是影响患者5年无病生存率的主要因素(P=0.008),病理T分期、原发灶NAC病理反应是影响患者5年总生存率的主要因素(均P<0.05)。Ⅲ期患者中,放疗组和未放疗组患者的5年局部区域复发率分别为1.9%和14.4%,差异有统计学意义(P=0.041);5年无病生存率分别为91.9%和67.4%,差异有统计学意义(P=0.022)。Ⅱ期患者中,放疗组和未放疗组患者的5年远处转移率分别为0和11.5%,差异有统计学意义(P=0.044);5年无病生存率分别为100.0%和84.9%,差异有统计学意义(P=0.023)。 结论: 临床T1~3N1M0期乳腺癌NAC和改良根治术后达到ypN0患者的的局部区域复发率较低,术后放疗能明显降低远处转移率并提高无病生存率,并且可以降低临床Ⅲ期患者的局部区域复发率。Ⅲ期患者需要术后放疗,Ⅱ期患者的放疗价值需要进一步研究。.
引用
- Rong QL, Wang SL, Tang Y, et al. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28635235. doi:10.3760/cma.j.issn.0253-3766.2017.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。